Selectivity-based QSAR approach for screening and evaluation of TRH analogs for TRH-R1 and TRH-R2 receptors subtypes

Journal of Molecular Graphics and Modelling

Volumn 27, Issue 3, 2008, Pages 309-320

  Kadam, Rameshwar U ^a   Chavan, Archana G ^a   Monga, Vikramdeep ^a   Kaur, Navneet ^a   Jain, Rahul ^a   Roy, Nilanjan ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

GFA; Selectivity based QSAR; TRH; TRH R1; TRH R2

Indexed keywords

GFA; SELECTIVITY-BASED QSAR; TRH; TRH-R1; TRH-R2;

PROTIRELIN DERIVATIVE; PROTIRELIN RECEPTOR; PROTIRELIN RECEPTOR 1; PROTIRELIN RECEPTOR 2; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

DRUG DESIGN; DRUG EVALUATION; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, THYROTROPIN-RELEASING HORMONE; REPRODUCIBILITY OF RESULTS; THYROTROPIN-RELEASING HORMONE;

EID: 53549113051     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2008.05.005     Document Type: Article

References (45)

1. Böler R., Enzman F., Folkers K., Bowers C., and Schally A.V. The identity of chemical and hormonal properties of the thyrotropin-releasing hormone and pyroglutamyl-histidyl-prolinamide. Biochem. Biophys. Res. Commun. 37 (1969) 705-710
2. Burgus R., Dunn T., Desiderio D., and Guillemin R. Derives Polypeptidiques de Syntheses Doues d'activite Hypophysiotropic TRF. C. R. Acad. Sci. 269 (1969) 1870-1873
3. Schally A.V., Bowers C.Y., Redding T.W., and Barrett J.F. Isolation of thyrotropin releasing factor (TRF) from porcine hypothalamus. Biochem. Biophys. Res. Commun. 25 (1966) 165-169
4. Keller H.H., Bartholini G., and Plestscher A. Enhancement of cerebral noradrenaline turnover by thyrotropin-releasing hormone. Nature 248 (1974) 528-529
5. Muller G.P., Chen H.J., and Meites J. In vivo stimulation of prolactin release in the rat by synthetic TRH. Proc. Soc. Exp. Biol. Med. 144 (1973) 613-615
6. Metcalf G. TRH: a possible mediator of thermoregulation. Nature 252 (1974) 310-311
7. Faden A.I., Sacksen I., and Noble L.J. Structure activity relationships of TRH analogs in experimental spinal injury. Brain Res. 448 (1988) 287-293
8. Salzman S.K., Hirofugi E., Knight P.B., Llados-Eckman C., Beckman A.L., and Winokur A. Treatment of experimental spinal trauma with thyrotropin-releasing hormone: central serotonergic and vascular mechanisms of action. Cent. Nerv. Syst. Trauma 4 (1987) 181-196
9. Prokai L. Central nervous system effects of thyrotropin-releasing hormone and its analogues: opportunities and perspectives for drug discovery and development. Prog. Drug Res. 59 (2002) 134-169
10. Straub R.E., French G.C., Joho R.H., and Gershengorn M.C. Expression cloning of a cDNA encoding the mouse pituitary thyrotropin-releasing hormone receptor. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 9514-9518
11. De la Pena P., Delgado L.M., Del Camino D., and Barros F. Two isoforms of the thyrotropin-releasing hormone receptor generated by alternative splicing have indistinguishable functional properties. J. Biol. Chem. 267 (1992) 25703-25708
12. Duthie S.M., Taylor P.L., Anderson L., Cook J., and Eidne K.A. Cloning and functional characterization of the human TRH receptor. Mol. Cell. Endocrinol. 95 (1993) R11-R15
13. Sun Y.M., Millar R.P., Ho H., Gershengorn M.C., and Illing N. Cloning and characterization of the chicken thyrotropin-releasing hormone receptor. Endocrinology 139 (1998) 3390-3398
14. Cao J., O'Donnell D., Vu H., Payza K., Pou C., Godbout C., Jakob A., Pelletier M., Lembo P., Ahmad S., and Walker P. Cloning and characterization of a cDNA encoding a novel subtype of rat thyrotropin-releasing hormone receptor. J. Biol. Chem. 273 (1998) 32281-32287
15. Harder S., Lu X., Wang W., Buck F., Gershengorn M.C., and Bruhn T.O. Regulator of G protein signaling 4 suppresses basal and thyrotropin-releasing hormone (TRH)-stimulated signaling by two mouse TRH receptors, TRH-R(1) and TRH-R(2). Endocrinology 142 (2001) 1188-1194
16. Itadani H., Nakamura T., Itoh J., Iwaasa H., Kanatani A., Borkowski J., Ihara M., and Ohta M. Cloning and characterization of a new subtype of thyrotropin-releasing hormone receptors. Biochem. Biophys. Res. Commun. 250 (1998) 68-71
17. O'Dowd B.F., Lee D.K., Huang W., Nguyen T., Cheng R., Liu Y., Wang B., Gershengorn M.C., and George S.R. TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared with TRH-R1. Mol. Endocrinol. 14 (2000) 183-193
18. Sun Y., Lu X., and Gershengorn M.C. Thyrotropin-releasing hormone receptors-similarities and differences. J. Mol. Endocrinol. 30 (2003) 87-97
19. Kaur N., Monga V., Lu X., Gershengorn M.C., and Jain R. Modifications of the pyroglutamic acid and histidine residues in thyrotropin-releasing hormone (TRH) yield analogs with selectivity for TRH receptor type 2 over type 1. Bioorg. Med. Chem. 15 (2007) 433-443
20. Kaur N., Monga V., Josan J.S., Lu X., Gershengorn M.C., and Jain R. Synthesis, receptor binding and activation studies of N(1)-alkyl-l-histidine containing thyrotropin-releasing hormone (TRH) analogues. Bioorg. Med. Chem. 14 (2006) 5980-5987
21. Engel S., Neumann S., Kaur N., Monga V., Jain R., Northup J., and Gershengorn M.C. Low affinity analogs of thyrotropin-releasing hormone are super-agonists. J. Biol. Chem. 281 (2006) 13103-13109
22. Kaur N., Lu X., Gershengorn M.C., and Jain R. Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype 2. J. Med. Chem. 48 (2005) 6162-6165
23. Jain R., Singh J., Perlman J.H., and Gershengorn M.C. Synthesis and biology of new thyrotropin-releasing hormone (TRH) analogues. Bioorg. Med. Chem. 10 (2002) 189-194
24. Perlman J.H., Colson A.O., Jain R., Czyzewski B., Cohen L.A., Osman R., and Gershengorn M.C. Role of the extracellular loops of the thyrotropin-releasing hormone receptor: evidence for an initial interaction with thyrotropin-releasing hormone. Biochemistry 36 (1997) 15670-15676
25. SYBYL, 7.1, Tripos Associates Inc., 1699, S. Hanley Road, St. Louis, MO631444, USA.
26. Dewar J.S., Zoebisch E.G., and Healy E.F. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985) 3902-3909
27. Linnan H., and Jurs P.C. Assessing the reliability of a QSAR model's predictions. J. Mol. Graph. Model. 23 (2005) 503-523
28. Kadam R.U., Garg D., Chavan A., and Roy N. Evaluation of Pseudomonas aeruginosa deacetylase LpxC inhibitory activity of dual PDE4-TNF-alpha inhibitors: a multiscreening approach. J. Chem. Inf. Model. 47 (2007) 1188-1195
29. Kadam R.U., and Roy N. Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors. Bioorg. Med. Chem. Lett. 19 (2006) 5136-5143
30. Mulliken R.S. Electronic population analysis on LCAO-MO molecular wave function I. J. Chem. Phys. 23 (1955) 1833-1846
31. Dragon, 5.3, Milano Chemometrics and QSAR Research Groups Inc., 2002.
32. R. Buigni, Quantitative structure activity relationships (QSAR) models of mutagens and carcinogens, pp. 1-40.
33. Basak S.C., Natarajan R., Mills D., Hawkins D.M., and Kraker J.J. Quantitative structure-activity relationship modeling of juvenile hormone mimetic compounds for Culex pipiens larvae, with a discussion of descriptor-thinning methods. J. Chem. Inf. Model. 46 (2006) 65-77
34. Rogers D., and Hopfinger A.J. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J. Chem. Inf. Comput. Sci. 34 (1994) 854-866
35. 2, Version 4.9, Accelrys Inc., 6985 Scranton Road, San Diego, CA, USA.
36. Leach A.R., and Gillet V.J. Molecular Descriptors (2003), Kluwer Academic Publishers pp. 53-75
37. J. Gasteiger, Chemoinformatics, A Textbook, Wiley-VCH, GmbH and Co., pp. 415-428.
38. R. Todeschini, V. Consoni, Handbook of Molecular Descriptors. In Method and Principals of Medicinal Chemistry, Wiley-VCH, pp. 492-513.
39. Hansch C., and Verma R.P. 20-(S)-Camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study. Chem. Med. Chem. 2 (2007) 1807-1813
40. Selassie C.D., Kapur S., Verma R.P., and Rosario M. Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study. J. Med. Chem. 48 (2005) 7234-7242
41. Tropsha A., Gramatica P., and Gombar V.K. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb. Sci. 22 (2003) 69-77
42. Wold S., and Eriksson L. In: van de Waterbeemd H. (Ed). Chemometrics Methods in Molecular Design (1995), Wiley-VCH, Weinheim 309-318
43. Melzig M.F., Tran G.D., Henke K., Selassie C.D., and Verma R.P. Inhibition of neutrophil elastase and thrombin activity by caffeic acid esters. Pharmazie 60 (2005) 869-873
44. 2!. J. Mol. Graph. Model. 20 (2002) 269-276
45. Walkera J.D., Carlsenb L., and Jaworskac J. Improving opportunities for regulatory acceptance of QSARs: the importance of model domain, uncertainty, validity and predictability. QSAR Comb. Sci. 22 (2003) 346-350